https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-01 / Leuk. Lymphoma 2004 Jul;45(7):1419-28
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-01 / Leuk. Lymphoma 2004 Jul;45(7):1419-282004-07-01 00:00:002019-02-15 08:51:04Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-852004-06-08 00:00:002019-02-15 08:50:26Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-522004-05-01 00:00:002019-02-15 08:51:06Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-72004-05-01 00:00:002021-11-15 15:38:16Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Klin Padiatr 2004 May-Jun;216(3):176-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Klin Padiatr 2004 May-Jun;216(3):176-822004-05-01 00:00:002019-02-15 09:12:31Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-532004-05-01 00:00:002019-02-15 08:53:29Dendritic cell vaccination in medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-512004-04-15 00:00:002019-02-15 08:39:06Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-302004-04-07 00:00:002019-02-15 08:50:36Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / Cancer Sci. 2004 Mar;95(3):248-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / Cancer Sci. 2004 Mar;95(3):248-532004-03-01 00:00:002019-02-15 08:48:24Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-03-01 / J. Exp. Clin. Cancer Res. 2004 Mar;23(1):9-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-03-01 / J. Exp. Clin. Cancer Res. 2004 Mar;23(1):9-132004-03-01 00:00:002019-02-15 08:51:05Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders
